Please ensure Javascript is enabled for purposes of website accessibility

Why Pieris Pharmaceuticals Inc. Is Soaring Today

By Brian Feroldi - Feb 9, 2018 at 12:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The signing of a lucrative collaboration deal causes the share price to jump.

What happened

In response to the company's new collaboration deal, shares of Pieris Pharmaceuticals (PIRS 2.37%), a clinical-stage biotech focused on cancer and other diseases, jumped as much as 16% in early morning trading on Friday. As of 12:15 p.m. EST, the stock was up 9%. 

So what

Pieris Pharmaceuticals stated that it has signed a new collaboration deal with Seattle Genetics (SGEN 2.12%), a biotechnology company that is also focused on cancer. The aim of this new partnership is to leverage both companies' expertise and technology to develop new immuno-oncology treatments for solid tumors and blood cancers.

This deal provides Pieris with an up-front payment of $30 million and the ability to earn up to $1.2 billion in milestone payments, plus double-digit royalties on any potential product sales.

Two businessmen looking over a contract

Image source: Getty Images.

While the companies will produce multiple compounds together, Seattle Genetics retains the option to select up to three products for further development. What's more, if the companies get to the pivotal-trial stage with a compound, then Pieris has the option to pick one compound and can share in global costs and profits on a 50-50 basis. 

This deal represents yet another vote of confidence for Pieris' technology, so it's easy to understand why investors are bidding up shares today. 

Now what

Pieris has a knack for getting deep-pocketed biopharma companies to help fund its growth. Last year, it successfully signed lucrative deals that featured up-front payments with a French pharma company called Servier and pharma giant AstraZeneca. In prior years, the company also earned payments from the likes of AllerganSanofiRoche, and Daiichi Sankyo.

My ears always perk up when I see a small-cap biotech with an interesting technology that grabs the attention of the industry giants. Today's announcement only enhances my interest in this company's future so I plan to follow Pieris' progress with great interest from here on out. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$141.39 (2.12%) $2.93
Pieris Pharmaceuticals, Inc. Stock Quote
Pieris Pharmaceuticals, Inc.
$1.73 (2.37%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.